Community Pharmacy, Geneva-Lausanne School of Pharmacy, Geneva, Switzerland, and Community Pharmacy of the Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Department of Clinical Neurosciences, Division of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Am J Health Syst Pharm. 2019 Jul 18;76(15):1150-1157. doi: 10.1093/ajhp/zxz106.
The development and dissemination of a specialty pharmacy service to optimize fingolimod therapy management are described.
Fingolimod was the first oral therapy developed to counter relapsing-remitting multiple sclerosis. Pharmacovigilance measures and individualized support are strongly recommended due to associated safety concerns. The Fingolimod Patient Support Program (F-PSP) was developed and disseminated within a community pharmacy network. The F-PSP aims to ensure responsible use of fingolimod and patient empowerment by promoting medication adherence and patient safety through a person-centered and integrated care approach. It complements basic pharmacy services through 2 interventions: medication adherence support and pharmacovigilance tailored to fingolimod. The adherence intervention combines motivational interviewing with longitudinal electronic medication adherence monitoring. The pharmacovigilance component consists of informing patients of fingolimod recommendations, reminding patients of recommended medical tests, and tracking and monitoring symptoms, especially those of potential serious adverse fingolimod reactions. A secure Web platform guides the pharmacist in conducting interviews and enables collection of patient-reported outcome data. A transition care pharmacist proposes program participation to all patients initiated on fingolimod, performs enrollment, and coordinates transfers to patient-designated community pharmacies for ongoing care.
The F-PSP enables support of individual patients, and also provides real-world data, helping to bridge the gap between practice and research. The F-PSP is intended to be a generic model of a specialty pharmacy service that is transferable to any other healthcare context, specialty drug or disease.
描述了优化芬戈莫德治疗管理的专业药房服务的开发和传播。
芬戈莫德是开发的第一种用于治疗复发缓解型多发性硬化症的口服疗法。由于存在相关安全问题，强烈建议采取药物警戒措施和个体化支持。芬戈莫德患者支持计划（F-PSP）在社区药房网络中开发和传播。F-PSP 旨在通过促进药物依从性和患者安全，通过以人为本和综合的护理方法，确保负责任地使用芬戈莫德并赋予患者权力。它通过 2 种干预措施补充了基本的药房服务：药物依从性支持和针对芬戈莫德的药物警戒。依从性干预措施将动机访谈与纵向电子药物依从性监测相结合。药物警戒部分包括告知患者芬戈莫德的建议，提醒患者进行推荐的医学检查，并跟踪和监测症状，特别是潜在的严重芬戈莫德不良反应的症状。一个安全的网络平台指导药剂师进行访谈，并能够收集患者报告的结果数据。过渡护理药剂师向所有开始使用芬戈莫德的患者提出参与计划的建议，进行注册，并协调向患者指定的社区药房转移，以进行持续护理。
F-PSP 能够支持个体患者，还提供真实世界的数据，有助于弥合实践和研究之间的差距。F-PSP 旨在成为一种专业药房服务的通用模式，可转移到任何其他医疗保健环境、特种药物或疾病。
